FAP and breast carcinoma: To further prove the selective binding capability of HFn-FAP nanoparticles, we included in our analysis two additional cellular models of human origin: human-activated myofibroblasts (HMfs, Figure S3b), where we previously documented stable FAP overexpression [40], and the MDA-MB-231 breast cancer cell line (Figure S3c).